Baton Rouge, Louisiana-based specialty chemicals maker Albemarle Corp, a global manufacturer of the anti-inflammatory agent ibuprofen, will increase the prices for its ibuprofen products $4.50/kg worldwide, effective October 1, or as contracts allow.
The price increase applies to Albemarle 40 and Albemarle 70 Ibuprofen grades (40- and 70-micron particle-size bulk products, respectively), as well as ALBE-TAB Ibuprofen products, which are direct compressible formulations optimized for tablet production.
"The global economy continues to drive both challenges and opportunities for Albemarle and our customers," said David Kuzy, business director of Albemarle's pharmaceutical actives group. "While raw materials have increased at an unprecedented rate over the past year, we have continued to invest in our business to ensure Albemarle meets the growing demands of our customers. This price increase will ensure we maintain the superior quality and delivery that our customers require and have come to expect from Albemarle," he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze